-
Pepgen pulls plug on exon-skipping therapy for Duchenne MD
Following lackluster data from a Phase 2 clinical trial, Pepgen will discontinue developing PGN-ED051, its experimental
-
Steroids and Stress Dosing: Understanding the Updated PJ Nicholoff Steroid Protocol
Last week, PPMD brought together leading experts to address steroids, stress dosing and the updated
-
MDA Ambassador Guest Blog: How My MG Journey Has Shaped Who I Am Today
Courtney B. is a passionate advocate for living life to the fullest despite the challenges
-
Why those of us with FSHD feel like we’re always in transition
During a recent facioscapulohumeral muscular dystrophy (FSHD) wellness group meeting via Zoom, we each shared
-
PepGen ends development of Duchenne Exon-51 skipping program
PepGen has ended clinical trials of PGN-EDO51, their investigational therapy for Duchenne patients amenable to skipping exon
-
A day of reflection leads me to a place of gratitude as a DMD mom
Once again, I’m writing from an uncomfortable chair in an infusion room as my son
-
My Father’s Journey with ALS
Father’s Day can be a beautiful celebration — but also a tender time for many.
-
Accessible Air Travel Is Ready for Takeoff. Can It Avoid Turbulence?
The past year featured the most disability-positive changes for air travel in decades. While there
-
Simply Stated: Updates in Ryanodine Receptor 1-Related Disorders (RYR-1-RD)
RYR-1-Related Disorders (RYR-1-RD) are a group of rare, inherited muscle disorders caused by variants in the
-
PepGen Announces Discontinuation of PGN-EDO51 Development
We are disappointed to share that PepGen Inc. announced the company’s decision to end development
